Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 4
2003-02-01
Irregular or prolonged menstrual bleeding and/or spotting are common side effects in patients
using progestin-only hormonal contraception such as levonorgestrel implants (Norplant).
Doxycycline, a drug approved by the Food and Drug Administration (FDA) to treat gum disease,
may reduce the occurrence of uterine bleeding and spotting in women who use Norplant. This
study will evaluate the effects of doxycycline on uterine bleeding/spotting in women using
Norplant.
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Completed
National Cancer Institute (NCI)
Phase 2
2008-03-10
This randomized phase II trial is studying how well levonorgestrel works in preventing
ovarian cancer in patients at high risk for ovarian cancer. Chemoprevention is the use of
certain drugs to keep cancer from forming. The use of levonorgestrel may prevent ovarian
cancer.
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Completed
Gynecologic Oncology Group
Phase 2
2008-03-10
This randomized phase II trial is studying how well levonorgestrel works in preventing
ovarian cancer in patients at high risk for ovarian cancer. Chemoprevention is the use of
certain drugs to keep cancer from forming. The use of levonorgestrel may prevent ovarian
cancer.
Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation
Completed
Columbia University
N/A
2007-09-01
Many women choose Depo-Provera for birth control because it is easy to use and very
effective. However, a significant number of Depo-Provera users experience irregular bleeding
during the first 90 days. Many users discontinue after their first injection due to irregular
bleeding. This study will evaluate the effect of using an estrogen vaginal ring during the
first 90 days of Depo-Provera use to see if it is acceptable to women and whether it
decreases irregular bleeding during the first 90 days of use and increases continuation to a
second injection.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
